Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Immunoprecipitation01:20

Immunoprecipitation

5.6K
Immunoprecipitation, or IP, is a widely used technique that employs protein-antibody interactions to isolate proteins or protein complexes in their native state for studying protein-protein interactions, quaternary structures, or supramolecular complexes. Various modifications of the technique, including chromatin IP, cross-linking IP, and fluorescence IP, are commonly used.
Chromatin Immunoprecipitation
Chromatin immunoprecipitation, also known as ChIP, is used to study protein-DNA or...
5.6K
Special Features of Adaptive Immunity01:20

Special Features of Adaptive Immunity

3.7K
The adaptive immune system, a crucial component of the overall immune response, offers a highly specialized defense against pathogens. It involves specific cell types and features, enabling it to combat infections effectively and efficiently.
The primary cell types involved in adaptive immunity are T cells and B cells. Each type has a unique role in defending the body against pathogens. T cells are responsible for cell-mediated immunity. They identify and eliminate infected cells directly,...
3.7K
Antigens Involved in Adaptive Immunity01:26

Antigens Involved in Adaptive Immunity

1.7K
An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and...
1.7K
Development of Immunocompetence01:22

Development of Immunocompetence

1.2K
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
1.2K
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

3.7K
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
3.7K
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

1.3K
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Practice parameter for inborn errors of immunity: What is new in the 2025 update.

The Journal of allergy and clinical immunology·2026
Same author

2025 Inborn errors of immunity practice parameter: Guidance from the Joint Task Force on Practice Parameters, the American Academy of Allergy, Asthma & Immunology (AAAAI), the American College of Allergy, Asthma and Immunology (ACAAI) and the Clinical Immunology Society (CIS).

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2026
Same author

The DNase TREX1 is a substrate of the intramembrane protease SPP with implications for disease pathogenesis.

Cellular and molecular life sciences : CMLS·2025
Same author

Gene therapy for inborn errors of immunity: Current clinical progress.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2025
Same author

Spectrum of clinical phenotypes of PLCG2 gene variants: Just PLAID.

The Journal of allergy and clinical immunology·2024
Same author

Insights from a single center registry of infant and toddler anaphylaxis: Food and fire ants.

The journal of allergy and clinical immunology. In practice·2023

Related Experiment Video

Updated: May 5, 2026

Interview: Glycolipid Antigen Presentation by CD1d and the Therapeutic Potential of NKT cell Activation
18:08

Interview: Glycolipid Antigen Presentation by CD1d and the Therapeutic Potential of NKT cell Activation

Published on: January 1, 2008

9.4K

Advances in basic and clinical immunology in 2011.

Javier Chinen1, William T Shearer

  • 1Allergy and Immunology Section, Department of Pediatrics, Baylor College of Medicine, Texas Children's Hospital, Houston, Tex 77030, USA.

The Journal of Allergy and Clinical Immunology
|December 31, 2011
PubMed
Summary

Advances in understanding primary immunodeficiencies in 2011 included T(H)17 cell differentiation, TACI mutations in CVID, and autoimmune frequencies. Novel diagnostics and improved treatments like gene therapy were also highlighted.

More Related Videos

Intralymphatic Immunotherapy and Vaccination in Mice
07:33

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

22.5K
Characterization of Thymus-dependent and Thymus-independent Immunoglobulin Isotype Responses in Mice Using Enzyme-linked Immunosorbent Assay
06:15

Characterization of Thymus-dependent and Thymus-independent Immunoglobulin Isotype Responses in Mice Using Enzyme-linked Immunosorbent Assay

Published on: September 7, 2018

9.0K

Related Experiment Videos

Last Updated: May 5, 2026

Interview: Glycolipid Antigen Presentation by CD1d and the Therapeutic Potential of NKT cell Activation
18:08

Interview: Glycolipid Antigen Presentation by CD1d and the Therapeutic Potential of NKT cell Activation

Published on: January 1, 2008

9.4K
Intralymphatic Immunotherapy and Vaccination in Mice
07:33

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

22.5K
Characterization of Thymus-dependent and Thymus-independent Immunoglobulin Isotype Responses in Mice Using Enzyme-linked Immunosorbent Assay
06:15

Characterization of Thymus-dependent and Thymus-independent Immunoglobulin Isotype Responses in Mice Using Enzyme-linked Immunosorbent Assay

Published on: September 7, 2018

9.0K

Area of Science:

  • Immunology
  • Genetics
  • Clinical Medicine

Background:

  • Primary immunodeficiencies (PIDs) research and clinical studies were prominent in 2011.
  • Progress was made in understanding T(H)17 cell differentiation and cytokines in inflammatory and infectious diseases.
  • The role of TACI mutations in Common Variable Immunodeficiency (CVID) and autoimmunity in DiGeorge syndrome were further elucidated.

Purpose of the Study:

  • To summarize key advancements in the understanding, diagnosis, and treatment of primary immunodeficiencies in 2011.
  • To highlight progress in characterizing T(H)17 cell pathways and genetic defects in PIDs.
  • To review novel diagnostic strategies and therapeutic interventions, including stem cell transplantation and gene therapy.

Main Methods:

  • Literature review and analysis of studies published in 2011 focusing on immunologic mechanisms and clinical aspects of PIDs.
  • Characterization of T(H)17 cell differentiation and cytokine roles in various disorders.
  • Investigation of genetic mutations (e.g., TACI) and their impact on B-cell function and disease pathogenesis.
  • Estimation of autoimmunity prevalence in specific PIDs like DiGeorge syndrome.
  • Development and feasibility assessment of novel newborn screening methods (e.g., for B-cell lymphopenia, adenosine deaminase deficiency).
  • Evaluation of treatment outcomes for hematopoietic stem cell transplantation and gene therapy approaches.

Main Results:

  • Significant progress in T(H)17 cell differentiation and cytokine roles in inflammatory disorders, HIV, and immunodysregulation.
  • TACI mutations identified as a likely cause of CVID by impairing B-cell function.
  • Autoimmunity observed in 8.5% of partial DiGeorge syndrome patients, primarily causing cytopenias and hypothyroidism.
  • Neoplasias, particularly lymphomas, frequently presented as the initial sign of PIDs.
  • Feasible large-scale newborn screening strategies for B-cell lymphopenia and adenosine deaminase deficiency were demonstrated.
  • Improved success rates for hematopoietic stem cell transplantation using unrelated donors and advancements in safer gene therapy techniques.
  • Development of induced pluripotent stem cells from PID patients for research.
  • New insights into uncommon PIDs, such as susceptibility to viral infections due to Toll-like receptor 3 pathway defects.

Conclusions:

  • The year 2011 saw substantial progress in understanding the immunologic basis of PIDs, leading to improved diagnostic and therapeutic strategies.
  • Novel screening methods and advanced treatments, including gene therapy and optimized stem cell transplantation, offer improved outcomes for PID patients.
  • Continued research into genetic defects and immune pathways is crucial for further enhancing the management of primary immunodeficiencies.